Oliver Lagore Vanvalin Investment Group Avidity Biosciences, Inc. Transaction History
Oliver Lagore Vanvalin Investment Group
- $263 Million
- Q2 2025
A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 663 shares of RNA stock, worth $46,940. This represents 0.01% of its overall portfolio holdings.
Number of Shares
663
Previous 663
-0.0%
Holding current value
$46,940
Previous $19,000
5.26%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
311Shares Held
139MCall Options Held
1.24MPut Options Held
526K-
Janus Henderson Group PLC London, X014.5MShares$1.03 Billion0.3% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$966 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY11.4MShares$805 Million6.62% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$713 Million0.08% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.79MShares$693 Million0.05% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $3.69B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...